BioSpace News Archive

It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 124,580 restricted stock units of Atara’s common stock to 35 newly hired employees and stock options to purchase an aggregate of 99,585 shares of Atara’s common stock to 12 such newly hired employees.

InMed Pharmaceuticals Inc., a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has closed the previously announced private placement.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Company’s common stock with an exercise price of $3.82 per share, the closing price of Assembly Bio’s common stock on July 1, 2021.

SANUWAVE Health, Inc., a leading provider of next-generation wound care products has announced that as of July 2, 2021 the company’s shares will no longer be traded on the OTCQB due to failure to timely file quarterly financials with the Securities & Exchange Commission.

SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 34,375 shares of Puma common stock to five new non-executive employees.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

Kiromic BioPharma, Inc., an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform that is used to develop novel oncology therapeutics, announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $5.00 per share, resulting in gross proceeds to the Company of $40 million.

Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of 20,440 restricted stock units.